Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
February 09 2024 - 4:30PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
Under
the Securities Exchange Act of 1934
(Amendment
No. 2)*
Deciphera
Pharmaceuticals, Inc.
(Name
of Issuer)
Common
Stock
(Title
of Class of Securities)
24344T101
(CUSIP
Number)
December
31, 2023
(Date
of Event which Requires filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ |
Rule
13d-1(b) |
☐ |
Rule
13d-1(c) |
☒ |
Rule
13d-1(d) |
*
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover
page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
CUSIP
No. 24344T101 |
Schedule
13G |
Page
2 of 5 Pages |
1 |
Names
of Reporting Persons
Brightstar
Associates LLC |
|
2 |
Check
the Appropriate Box if a Member of a Group |
(a) [ ]
(b) [ ]
|
3 |
SEC
Use Only
|
|
4 |
Citizen
or Place of Organization
Missouri |
|
Number
of Shares Beneficially Owned by Each Reporting Person With
|
5 |
Sole
Voting Power
23,059,708 |
6 |
Shared
Voting Power
0 |
7 |
Sole
Dispositive Power
23,059,708 |
8 |
Shared
Dispositive Power
0 |
9 |
Aggregate
Amount Beneficially Owned by Each Reporting Person
23,059,708 |
|
10 |
Check if the Aggregate Amount in Row (9) Excludes Certain Shares
|
[ ] |
11 |
Percent
of a Class Represented by Amount in Row 9
28.2% |
|
12 |
Type of Reporting Person
Limited Liability Company |
|
CUSIP
No. 24344T101 |
Schedule
13G |
Page
3 of 5 Pages |
ITEM
1. |
(a) | Name
of Issuer: |
Deciphera
Pharmaceuticals, Inc. (the “Issuer”).
|
(b) |
Address of Issuer’s Principal Executive Offices: |
200
Smith Street, Waltham, MA 02451
ITEM
2. |
(a) | Name
of Person Filing: |
This
statement is filed on behalf of Brightstar Associates LLC (the “Reporting Person”).
|
(b) | Address or Principal
Business Office: |
The
business address of the Reporting Person is 1020 Central Street, Suite 300, Kansas City, Missouri 64105.
|
(c) | Citizenship of
each Reporting Person is: |
The
Reporting Person is incorporated in the State of Missouri.
|
(d) | Title of Class
of Securities: |
Common
Stock, par value $0.01 per share (the “Common Stock”).
24344T101
ITEM
3.
Not
applicable.
The
ownership information presented below represents beneficial ownership of shares of Common Stock of the Issuer as of the date of this
filing, based upon 80,800,062 shares of Common Stock outstanding as of January 31, 2024, as disclosed in the Issuer’s annual report
on Form 10-K as filed with the Securities and Exchange Commission on February 6, 2024.
(a)
Amount beneficially owned:
The
Reporting Person is the record holder of 23,059,708 shares of Common Stock and a currently exercisable warrant for the purchase of up
to an additional 48,136 shares of Common Stock. The warrant contains a limitation on exercise that provides that the warrant may not
be exercised to the extent that it would cause the Reporting Person to beneficially own more than 28.22% of the then-outstanding Common
Stock.
CUSIP
No. 24344T101 |
Schedule
13G |
Page
4 of 5 Pages |
The
Reporting Person is managed by a three-person managing board consisting of Greg A. Hamilton, Mark K. Fallon, and Timothy Fritzel, and
all action relating to the voting or disposition of these shares requires approval of a majority of the board. Such individuals expressly
disclaim any beneficial ownership over the shares held by the Reporting Person.
(b)
Percent of class: 28.2%
(c)
Number of shares as to which the person has:
|
(i) | Sole power to vote
or to direct the vote: 23,059,708 |
|
(ii) | Shared power to
vote or direct the vote: 0 |
|
(iii) | Sole power to dispose
or to direct the disposition of: 23,059,708 |
|
(iv) | Shared power to
dispose or to direct the disposition of: 0 |
ITEM
5. | Ownership
of Five Percent or Less of a Class |
Not
applicable.
ITEM
6. | Ownership
of More than Five Percent on Behalf of Another Person |
Not
applicable.
ITEM
7. | Identification
and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent
Holding Company |
Not
applicable.
ITEM
8. | Identification
and Classification of Members of the Group |
Not
applicable.
ITEM
9. | Notice
of Dissolution of Group |
Not
applicable.
Not
applicable.
CUSIP
No. 24344T101 |
Schedule
13G |
Page
5 of 5 Pages |
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Date:
February 9, 2024
|
Brightstar
Associates LLC |
|
|
|
|
By: |
/s/
Greg A. Hamilton |
|
Name: |
Greg
A. Hamilton |
|
Title: |
Member
of the Board of Managers |
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024